{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:01:23Z","timestamp":1776988883452,"version":"3.51.4"},"reference-count":122,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1136\/annrheumdis-2013-205139","type":"journal-article","created":{"date-parts":[[2014,4,17]],"date-time":"2014-04-17T04:10:16Z","timestamp":1397707816000},"page":"958-967","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":639,"title":["Treat-to-target in systemic lupus erythematosus: recommendations from an international task force"],"prefix":"10.1016","volume":"73","author":[{"given":"Ronald F","family":"van Vollenhoven","sequence":"first","affiliation":[]},{"given":"Marta","family":"Mosca","sequence":"additional","affiliation":[]},{"given":"George","family":"Bertsias","sequence":"additional","affiliation":[]},{"given":"David","family":"Isenberg","sequence":"additional","affiliation":[]},{"given":"Annegret","family":"Kuhn","sequence":"additional","affiliation":[]},{"given":"Kirsten","family":"Lerstr\u00f8m","sequence":"additional","affiliation":[]},{"given":"Martin","family":"Aringer","sequence":"additional","affiliation":[]},{"given":"Hendrika","family":"Bootsma","sequence":"additional","affiliation":[]},{"given":"Dimitrios","family":"Boumpas","sequence":"additional","affiliation":[]},{"given":"Ian N","family":"Bruce","sequence":"additional","affiliation":[]},{"given":"Ricard","family":"Cervera","sequence":"additional","affiliation":[]},{"given":"Ann","family":"Clarke","sequence":"additional","affiliation":[]},{"given":"Nathalie","family":"Costedoat-Chalumeau","sequence":"additional","affiliation":[]},{"given":"L\u00e1szl\u00f3","family":"Czirj\u00e1k","sequence":"additional","affiliation":[]},{"given":"Ronald","family":"Derksen","sequence":"additional","affiliation":[]},{"given":"Thomas","family":"D\u00f6rner","sequence":"additional","affiliation":[]},{"given":"Caroline","family":"Gordon","sequence":"additional","affiliation":[]},{"given":"Winfried","family":"Graninger","sequence":"additional","affiliation":[]},{"given":"Fr\u00e9d\u00e9ric","family":"Houssiau","sequence":"additional","affiliation":[]},{"given":"Murat","family":"Inanc","sequence":"additional","affiliation":[]},{"given":"S\u00f8ren","family":"Jacobsen","sequence":"additional","affiliation":[]},{"given":"David","family":"Jayne","sequence":"additional","affiliation":[]},{"given":"Anna","family":"Jedryka-Goral","sequence":"additional","affiliation":[]},{"given":"Adrian","family":"Levitsky","sequence":"additional","affiliation":[]},{"given":"Roger","family":"Levy","sequence":"additional","affiliation":[]},{"given":"Xavier","family":"Mariette","sequence":"additional","affiliation":[]},{"given":"Eric","family":"Morand","sequence":"additional","affiliation":[]},{"given":"Sandra","family":"Navarra","sequence":"additional","affiliation":[]},{"given":"Irmgard","family":"Neumann","sequence":"additional","affiliation":[]},{"given":"Anisur","family":"Rahman","sequence":"additional","affiliation":[]},{"given":"Jozef","family":"Rovensk\u00fd","sequence":"additional","affiliation":[]},{"given":"Josef","family":"Smolen","sequence":"additional","affiliation":[]},{"given":"Carlos","family":"Vasconcelos","sequence":"additional","affiliation":[]},{"given":"Alexandre","family":"Voskuyl","sequence":"additional","affiliation":[]},{"given":"Anne","family":"Voss","sequence":"additional","affiliation":[]},{"given":"Helena","family":"Zakharova","sequence":"additional","affiliation":[]},{"given":"Asad","family":"Zoma","sequence":"additional","affiliation":[]},{"given":"Matthias","family":"Schneider","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1136\/annrheumdis-2013-205139_bib1","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0140-6736(94)91405-2","article-title":"Pharmacological treatment of hypertension","volume":"344","author":"Swales","year":"1994","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1136\/annrheumdis-2013-205139_bib2","doi-asserted-by":"crossref","first-page":"SI29","DOI":"10.1016\/S0140-6736(97)90026-X","article-title":"The impact of cardiovascular disease on people with diabetes: the potential for prevention","volume":"350","author":"Eastman","year":"1997","journal-title":"Lancet"},{"key":"10.1136\/annrheumdis-2013-205139_bib3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","article-title":"Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial","volume":"364","author":"Grigor","year":"2004","journal-title":"Lancet"},{"key":"10.1136\/annrheumdis-2013-205139_bib4","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1136\/ard.2007.071092","article-title":"Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)","volume":"66","author":"Verstappen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-205139_bib5","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/S0140-6736(98)08513-4","article-title":"Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group","volume":"353","author":"Mottonen","year":"1999","journal-title":"Lancet"},{"key":"10.1136\/annrheumdis-2013-205139_bib6","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","article-title":"Treating rheumatoid arthritis to target: recommendations of an international task force","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-205139_bib7","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/annrheumdis-2013-203419","article-title":"Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-205139_bib8","first-page":"1398","article-title":"High predictive value of the Systemic Lupus International Collaborating Clinics\/American College of Rheumatology damage index for survival in systemic lupus erythematosus","volume":"29","author":"Nived","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2013-205139_bib9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/qhc.12.1.18","article-title":"Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project","volume":"12","author":"AGREE Collaboration","year":"2003","journal-title":"Qual Saf Health Care"},{"key":"10.1136\/annrheumdis-2013-205139_bib10","unstructured":"Group OLoEW. OCEBM Levels of Evidence Working Group. The Oxford Levels of Evidence 2. Oxford Centre for Evidence-Based Medicine. http:\/\/www.cebm.net\/index.aspx?o=5653. In: Group OLoEW, ed., 2011."},{"key":"10.1136\/annrheumdis-2013-205139_bib11","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1136\/ard.2009.117200","article-title":"European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies","volume":"69","author":"Mosca","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-205139_bib12","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/art.1780390303","article-title":"The development and initial validation of the Systemic Lupus International Collaborating Clinics\/American College of Rheumatology damage index for systemic lupus erythematosus","volume":"39","author":"Gladman","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-205139_bib13","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1002\/art.34672","article-title":"Predictors of organ damage in systemic lupus erythematosus: The Hopkins Lupus Cohort","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-205139_bib14","first-page":"1977","article-title":"Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus","volume":"30","author":"Ibanez","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2013-205139_bib15","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/art.22375","article-title":"Accelerated damage accrual among men with systemic lupus erythematosus: XLIV. Results from a multiethnic US cohort","volume":"56","author":"Andrade","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-205139_bib16","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/rheumatology\/ker368","article-title":"Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort","volume":"51","author":"Lopez","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/annrheumdis-2013-205139_bib17","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1093\/rheumatology\/kem153","article-title":"Systemic lupus erythematosus in a multiethnic US cohort LUMINA LI: anaemia as a predictor of disease activity and damage accrual","volume":"46","author":"Bertoli","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/annrheumdis-2013-205139_bib18","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1093\/rheumatology\/keh238","article-title":"Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus\u2014a 5-yr prospective study","volume":"43","author":"Stoll","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/annrheumdis-2013-205139_bib19","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1136\/ard.2007.077594","article-title":"Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV)","volume":"67","author":"Andrade","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-205139_bib20","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/ard.61.12.1065","article-title":"Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus","volume":"61","author":"Manger","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-205139_bib21","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1136\/annrheumdis-2011-200384","article-title":"Long-term follow-up of a randomised controlled trial of azathioprine\/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis","volume":"71","author":"Arends","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-205139_bib22","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/ki.2010.525","article-title":"Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus","volume":"79","author":"Reich","year":"2011","journal-title":"Kidney Int"},{"key":"10.1136\/annrheumdis-2013-205139_bib23","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1002\/art.21929","article-title":"Association between serum total cholesterol level and renal outcome in systemic lupus erythematosus","volume":"54","author":"Tisseverasinghe","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-205139_bib24","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/00005792-199603000-00005","article-title":"Remission of systematic lupus erythematosus","volume":"75","author":"Drenkard","year":"1996","journal-title":"Medicine"},{"key":"10.1136\/annrheumdis-2013-205139_bib25","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1177\/0961203310366572","article-title":"Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus","volume":"19","author":"Nossent","year":"2010","journal-title":"Lupus"},{"key":"10.1136\/annrheumdis-2013-205139_bib26","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/art.10142","article-title":"Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies","volume":"46","author":"Illei","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-205139_bib27","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1002\/art.20364","article-title":"Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis","volume":"50","author":"Mok","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-205139_bib28","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.semarthrit.2011.08.002","article-title":"Membranous nephropathy in systemic lupus erythematosus: long-term outcome and prognostic factors of 103 patients","volume":"41","author":"Moroni","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-205139_bib29","unstructured":"Morand E, Franklyn K, Lau CS, et al. Consensus Definition and Preliminary Validation of a Low Disease Activity State in Systemic Lupus Erythematosus. Poster, ACR Annual Congress, 2013."},{"key":"10.1136\/annrheumdis-2013-205139_bib30","first-page":"490","article-title":"Outcome measures to be used in clinical trials in systemic lupus erythematosus","volume":"26","author":"Strand","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2013-205139_bib31","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-205139_bib32","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/rheumatology\/kep396","article-title":"The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE","volume":"49","author":"Griffiths","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/annrheumdis-2013-205139_bib33","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1177\/0961203310395802","article-title":"Assessment of flares in lupus patients enrolled in a phase II\/III study of rituximab (EXPLORER)","volume":"20","author":"Merrill","year":"2011","journal-title":"Lupus"},{"key":"10.1136\/annrheumdis-2013-205139_bib34","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"10.1136\/annrheumdis-2013-205139_bib35","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","article-title":"Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis","volume":"365","author":"Dooley","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1136\/annrheumdis-2013-205139_bib36","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1136\/ard.2010.131995","article-title":"Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial","volume":"69","author":"Houssiau","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-205139_bib37","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1093\/ndt\/gfm245","article-title":"The long-term outcome of 93 patients with proliferative lupus nephritis","volume":"22","author":"Moroni","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1136\/annrheumdis-2013-205139_bib38","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1046\/j.1523-1755.2002.00280.x","article-title":"Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis","volume":"61","author":"Mosca","year":"2002","journal-title":"Kidney Int"},{"key":"10.1136\/annrheumdis-2013-205139_bib39","first-page":"1467","article-title":"Prolonged remission in systemic lupus erythematosus","volume":"32","author":"Urowitz","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2013-205139_bib40","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1002\/art.24937","article-title":"Distinct subtypes of myelitis in systemic lupus erythematosus","volume":"60","author":"Birnbaum","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-205139_bib41","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1136\/ard.48.6.447","article-title":"Systemic lupus erythematosus. I. Outcome and survival: Dutch experience with 110 patients studied prospectively","volume":"48","author":"Swaak","year":"1989","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-205139_bib42","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1191\/0961203306lu2316oa","article-title":"Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus","volume":"15","author":"Bandeira","year":"2006","journal-title":"Lupus"},{"key":"10.1136\/annrheumdis-2013-205139_bib43","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/0961203309351033","article-title":"SLE disease patterns in a Danish population-based lupus cohort: an 8-year prospective study","volume":"19","author":"Laustrup","year":"2010","journal-title":"Lupus"},{"key":"10.1136\/annrheumdis-2013-205139_bib44","first-page":"1513","article-title":"Damage accrual in southern Chinese patients with systemic lupus erythematosus","volume":"30","author":"Mok","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2013-205139_bib45","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1002\/1529-0131(200110)44:10<2350::AID-ART398>3.0.CO;2-A","article-title":"A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus","volume":"44","author":"Ho","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-205139_bib46","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/1529-0131(200110)44:10<2342::AID-ART397>3.0.CO;2-8","article-title":"Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus","volume":"44","author":"Ho","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-205139_bib47","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/rheumatology\/39.12.1316","article-title":"Prognostic parameters for flare in systemic lupus erythematosus","volume":"39","author":"Mirzayan","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/annrheumdis-2013-205139_bib48","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.3899\/jrheum.090019","article-title":"Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective study","volume":"36","author":"Petri","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2013-205139_bib49","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/ard.45.5.359","article-title":"Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus","volume":"45","author":"Swaak","year":"1986","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-205139_bib50","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/art.1780330505","article-title":"Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study","volume":"33","author":"ter Borg","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-205139_bib51","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/art.22356","article-title":"Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus","volume":"55","author":"Ng","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-205139_bib52","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/rheumatology\/41.1.62","article-title":"IgG subclass distribution of autoantibodies differs between renal and extra-renal relapses in patients with systemic lupus erythematosus","volume":"41","author":"Bijl","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/annrheumdis-2013-205139_bib53","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1177\/0961203310371154","article-title":"The complex nature of serum C3 and C4 as biomarkers of lupus renal flare","volume":"19","author":"Birmingham","year":"2010","journal-title":"Lupus"},{"key":"10.1136\/annrheumdis-2013-205139_bib54","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/S0140-6736(95)90114-0","article-title":"Prevention of relapses in systemic lupus erythematosus","volume":"345","author":"Bootsma","year":"1995","journal-title":"Lancet"},{"key":"10.1136\/annrheumdis-2013-205139_bib55","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1002\/art.22198","article-title":"The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial","volume":"54","author":"Tseng","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-205139_bib56","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.3899\/jrheum.100007","article-title":"Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome","volume":"37","author":"Steiman","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2013-205139_bib57","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/acr.21568","article-title":"Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period","volume":"64","author":"Steiman","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1136\/annrheumdis-2013-205139_bib58","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/rheumatology\/kep062","article-title":"Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years","volume":"48","author":"Chambers","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/annrheumdis-2013-205139_bib59","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1136\/annrheumdis-2011-201089","article-title":"Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study","volume":"71","author":"Hanly","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-205139_bib60","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.semarthrit.2011.11.002","article-title":"Global trend of survival and damage of systemic lupus erythematosus: meta-analysis and meta-regression of observational studies from the 1950s to 2000s","volume":"41","author":"Mak","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-205139_bib61","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/0961203307086639","article-title":"Time to seizure occurrence and damage in PROFILE, a multi-ethnic systemic lupus erythematosus cohort","volume":"17","author":"Ramsey-Goldman","year":"2008","journal-title":"Lupus"},{"key":"10.1136\/annrheumdis-2013-205139_bib62","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s11926-013-0380-9","article-title":"Top 10 recent developments in health-related quality of life in patients with systemic lupus erythematosus","volume":"15","author":"Dua","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"10.1136\/annrheumdis-2013-205139_bib63","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s11926-010-0114-1","article-title":"Quality-of-life measurements versus disease activity in systemic lupus erythematosus","volume":"12","author":"Kiani","year":"2010","journal-title":"Curr Rheumatol Rep"},{"key":"10.1136\/annrheumdis-2013-205139_bib64","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/ard.2008.094763","article-title":"Lupus-specific health outcome measure for US patients: the LupusQoL-US version","volume":"69","author":"Jolly","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-205139_bib65","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.3899\/jrheum.091277","article-title":"The LupusQoL and associations with demographics and clinical measurements in patients with systemic lupus erythematosus","volume":"37","author":"McElhone","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2013-205139_bib66","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3899\/jrheum.090876","article-title":"Relationship between flare and health-related quality of life in patients with systemic lupus erythematosus","volume":"37","author":"Zhu","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2013-205139_bib67","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.3899\/jrheum.081022","article-title":"Psychometric properties of the EuroQol-5D and Short Form-6D in patients with systemic lupus erythematosus","volume":"36","author":"Aggarwal","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2013-205139_bib68","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1093\/rheumatology\/keh392","article-title":"Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological and psychological determinants","volume":"43","author":"Doria","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/annrheumdis-2013-205139_bib69","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/acr.20503","article-title":"Brief index of lupus damage: a patient-reported measure of damage in systemic lupus erythematosus","volume":"63","author":"Yazdany","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1136\/annrheumdis-2013-205139_bib70","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3899\/jrheum.080822","article-title":"The relationship between renal activity and quality of life in systemic lupus erythematosus","volume":"36","author":"Appenzeller","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2013-205139_bib71","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/art.23339","article-title":"Quality of life over time in patients with systemic lupus erythematosus","volume":"59","author":"Kuriya","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-205139_bib72","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/03009740802415527","article-title":"Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study","volume":"38","author":"Mok","year":"2009","journal-title":"Scand J Rheumatol"},{"key":"10.1136\/annrheumdis-2013-205139_bib73","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1177\/0961203308101718","article-title":"Relationship between health-related quality of life and SLE activity and damage in children over time","volume":"18","author":"Moorthy","year":"2009","journal-title":"Lupus"},{"key":"10.1136\/annrheumdis-2013-205139_bib74","first-page":"1699","article-title":"Health-related quality of life and treatment burden in patients with proliferative lupus nephritis treated with cyclophosphamide or azathioprine\/methylprednisolone in a randomized controlled trial","volume":"34","author":"Grootscholten","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2013-205139_bib75","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1191\/0961203303lu440oa","article-title":"Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo","volume":"12","author":"Strand","year":"2003","journal-title":"Lupus"},{"key":"10.1136\/annrheumdis-2013-205139_bib76","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/annrheumdis-2011-200937","article-title":"Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response","volume":"71","author":"van Vollenhoven","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-205139_bib77","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s10067-011-1778-2","article-title":"Predictive value of remission status after 6 months induction therapy in patients with proliferative lupus nephritis: a retrospective analysis","volume":"30","author":"So","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1136\/annrheumdis-2013-205139_bib78","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/acr.20116","article-title":"Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis","volume":"62","author":"Faurschou","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1136\/annrheumdis-2013-205139_bib79","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/acr.20397","article-title":"Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide","volume":"63","author":"Dall'era","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1136\/annrheumdis-2013-205139_bib80","first-page":"779","article-title":"The clinical and renal biopsy predictors of long-term outcome in lupus nephritis: a study of 87 patients and review of the literature","volume":"72","author":"Esdaile","year":"1989","journal-title":"Q J Med"},{"key":"10.1136\/annrheumdis-2013-205139_bib81","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1046\/j.1523-1755.2000.00832.x","article-title":"Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide","volume":"57","author":"Ioannidis","year":"2000","journal-title":"Kidney Int"},{"key":"10.1136\/annrheumdis-2013-205139_bib82","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1080\/03009749950155464","article-title":"Prognostic value of renal biopsy and clinical variables in patients with lupus nephritis and normal serum creatinine","volume":"28","author":"Jacobsen","year":"1999","journal-title":"Scand J Rheumatol"},{"key":"10.1136\/annrheumdis-2013-205139_bib83","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1191\/096120399678840828","article-title":"Risk factors for hypercreatinemia in patients with systemic lupus erythematosus","volume":"8","author":"Rzany","year":"1999","journal-title":"Lupus"},{"key":"10.1136\/annrheumdis-2013-205139_bib84","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/BF00878876","article-title":"Lupus transverse myelopathy: better outcome with early recognition and aggressive high-dose intravenous corticosteroid pulse treatment","volume":"242","author":"Harisdangkul","year":"1995","journal-title":"J Neurol"},{"key":"10.1136\/annrheumdis-2013-205139_bib85","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1177\/0961203307088005","article-title":"Prognostic factors of lupus myelopathy","volume":"17","author":"Lu","year":"2008","journal-title":"Lupus"},{"key":"10.1136\/annrheumdis-2013-205139_bib86","first-page":"CD002265","article-title":"Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus","volume":"2","author":"Fernandes Moca Trevisani","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1136\/annrheumdis-2013-205139_bib87","first-page":"CD002922","article-title":"Treatment for lupus nephritis","volume":"12","author":"Henderson","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1136\/annrheumdis-2013-205139_bib88","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/0140-6736(92)92292-N","article-title":"Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis","volume":"340","author":"Boumpas","year":"1992","journal-title":"Lancet"},{"key":"10.1136\/annrheumdis-2013-205139_bib89","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/art.1780180106","article-title":"Long-term maintenance therapy with azathioprine in systemic lupus erythematosus","volume":"18","author":"Ginzler","year":"1975","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-205139_bib90","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.amjmed.2005.08.045","article-title":"Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide","volume":"119","author":"Mok","year":"2006","journal-title":"Am J Med"},{"key":"10.1136\/annrheumdis-2013-205139_bib91","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/ard.2008.102533","article-title":"The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide","volume":"69","author":"Houssiau","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-205139_bib92","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.3899\/jrheum.101249","article-title":"Longterm followup after tapering mycophenolate mofetil during maintenance treatment for proliferative lupus nephritis","volume":"38","author":"Laskari","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2013-205139_bib93","doi-asserted-by":"crossref","unstructured":"Yap DY, Ma MK, Mok MM, et al. Long-term data on corticosteroids and mycophenolate mofetil treatment in lupus nephritis. Rheumatology (Oxford) 2013;52:480\u20136.","DOI":"10.1093\/rheumatology\/kes293"},{"key":"10.1136\/annrheumdis-2013-205139_bib94","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3899\/jrheum.080828","article-title":"Prednisone, lupus activity, and permanent organ damage","volume":"36","author":"Thamer","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2013-205139_bib95","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/annrheumdis-2011-200106","article-title":"A longitudinal PRINTO study on growth and puberty in juvenile systemic lupus erythematosus","volume":"71","author":"Rygg","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-205139_bib96","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3899\/jrheum.110851","article-title":"Adverse events during longterm low-dose glucocorticoid treatment of polymyalgia rheumatica: a retrospective study","volume":"39","author":"Mazzantini","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2013-205139_bib97","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.3899\/jrheum.100461","article-title":"Incident comorbidity among patients with rheumatoid arthritis treated or not with low-dose glucocorticoids: a retrospective study","volume":"37","author":"Mazzantini","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2013-205139_bib98","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1191\/0961203304lu2030oa","article-title":"Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus","volume":"13","author":"Ruiz-Irastorza","year":"2004","journal-title":"Lupus"},{"key":"10.1136\/annrheumdis-2013-205139_bib99","first-page":"622","article-title":"Antiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosus","volume":"32","author":"Mok","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2013-205139_bib100","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/0961203306074767","article-title":"Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients","volume":"16","author":"Tarr","year":"2007","journal-title":"Lupus"},{"key":"10.1136\/annrheumdis-2013-205139_bib101","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(10)60709-X","article-title":"Antiphospholipid syndrome","volume":"376","author":"Ruiz-Irastorza","year":"2010","journal-title":"Lancet"},{"key":"10.1136\/annrheumdis-2013-205139_bib102","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/art.24232","article-title":"Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies","volume":"61","author":"Tektonidou","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-205139_bib103","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1056\/NEJMoa035241","article-title":"A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome","volume":"349","author":"Crowther","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1136\/annrheumdis-2013-205139_bib104","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1538-7836.2005.01340.x","article-title":"A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)","volume":"3","author":"Finazzi","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1136\/annrheumdis-2013-205139_bib105","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJM199504133321504","article-title":"The management of thrombosis in the antiphospholipid-antibody syndrome","volume":"332","author":"Khamashta","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1136\/annrheumdis-2013-205139_bib106","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1177\/0961203309103303","article-title":"Clinical manifestations and outcomes of antithrombotic treatment of the Tan Tock Seng Hospital Singapore antiphospholipid syndrome cohort","volume":"18","author":"Tan","year":"2009","journal-title":"Lupus"},{"key":"10.1136\/annrheumdis-2013-205139_bib107","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.2008.101766","article-title":"Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review","volume":"69","author":"Ruiz-Irastorza","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-205139_bib108","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1191\/096120398678919778","article-title":"A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group","volume":"7","author":"Tsakonas","year":"1998","journal-title":"Lupus"},{"key":"10.1136\/annrheumdis-2013-205139_bib109","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1002\/art.21358","article-title":"Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus","volume":"52","author":"Bezerra","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-205139_bib110","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1177\/0961203308101714","article-title":"Treatment of lupus skin involvement with quinacrine and hydroxychloroquine","volume":"18","author":"Cavazzana","year":"2009","journal-title":"Lupus"},{"key":"10.1136\/annrheumdis-2013-205139_bib111","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/art.21039","article-title":"Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual","volume":"52","author":"Fessler","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-205139_bib112","first-page":"824","article-title":"Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE","volume":"32","author":"Ibanez","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2013-205139_bib113","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/0961203306071872","article-title":"Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus","volume":"15","author":"Ruiz-Irastorza","year":"2006","journal-title":"Lupus"},{"key":"10.1136\/annrheumdis-2013-205139_bib114","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.3899\/jrheum.080214","article-title":"Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus","volume":"35","author":"Urowitz","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2013-205139_bib115","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1177\/0961203312445230","article-title":"Predictors of survival in Chinese patients with lupus nephritis","volume":"21","author":"Zheng","year":"2012","journal-title":"Lupus"},{"key":"10.1136\/annrheumdis-2013-205139_bib116","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1093\/rheumatology\/ken208","article-title":"Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus\u2014results from LUMINA (LIX): a multiethnic US cohort","volume":"47","author":"Duran-Barragan","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/annrheumdis-2013-205139_bib117","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1212\/01.WNL.0000149640.78684.EA","article-title":"Predictors of cognitive dysfunction in patients with systemic lupus erythematosus","volume":"64","author":"McLaurin","year":"2005","journal-title":"Neurology"},{"key":"10.1136\/annrheumdis-2013-205139_bib118","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1177\/0961203309105877","article-title":"Peripheral vascular damage in systemic lupus erythematosus: data from LUMINA, a large multi-ethnic U.S. cohort (LXIX)","volume":"18","author":"Burgos","year":"2009","journal-title":"Lupus"},{"key":"10.1136\/annrheumdis-2013-205139_bib119","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.24379","article-title":"Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo-controlled study","volume":"60","author":"Norby","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-205139_bib120","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/ard.2010.136762","article-title":"Lupus Atherosclerosis Prevention Study (LAPS)","volume":"70","author":"Petri","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-205139_bib121","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1136\/ard.2007.079095","article-title":"Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response","volume":"67","author":"Jonsdottir","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-205139_bib122","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1002\/art.27541","article-title":"Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry","volume":"62","author":"Terrier","year":"2010","journal-title":"Arthritis Rheum"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724148959?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724148959?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/annrheumdis-2013-205139","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T11:34:45Z","timestamp":1736076885000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724148959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":122,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0003496724148959"],"URL":"https:\/\/doi.org\/10.1136\/annrheumdis-2013-205139","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treat-to-target in systemic lupus erythematosus: recommendations from an international task force","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/annrheumdis-2013-205139","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 \u00a9 2014, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}